Autologous Native ESR1-pulsed DC1 Vaccine Alternating with Autologous Mutated ESR1-pulsed DC1 Vaccine

**Semantic type:** Cell|Immunologic Factor|Pharmacologic Substance

**Definition:** A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DC1s) pulsed with either native or mutated estrogen receptor alpha (ERa; estrogen receptor 1; ESR1), with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated to produce DC1s and pulsed with either native or mutated ESR1. Alternating weekly between autologous native ESR1-pulsed and mutated ESR1-pulsed DC1 vaccine, upon administration, the autologous native and/or mutated ESR1-pulsed DC1 vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against ESR1-positive tumor cells, which may result in tumor cell death and decreased tumor growth. ESR1 is overexpressed and/or mutated in certain cancers.

**Synonyms:** - Autologous DC1s Pulsed with Native or Mutated ESR1 - Autologous Native ESR1-pulsed DC1s/Mutated ESR1-pulsed DC1s